Xilio Therapeutics shares underperformed the S&P 500 so far this year, based on events of August 14, 2025.
Steady: 1 development in the last 24 hours, 1 in the last 7 days
Updated 2 hours ago
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Xilio Therapeutics shares underperformed the S&P 500 so far this year, based on events of August 14, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Raymond James Financial assumed coverage on Xilio Therapeutics shares.Sub-event
Xilio Therapeutics shares underperformed the S&P 500 this year.1 source
Keep exploring
The entities involved
-
Xilio Therapeutics (United States)
organization
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksXilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss